RC
GLUE icon

Rangeley Capital’s Monte Rosa Therapeutics GLUE Stock Holding History

Rangeley Capital’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-27,016
Closed -$444K – 191
2026
Q1 		$444K Sell
27,016
-40,484
-60% -$774K 0.43% 49
2025
Q4 		$1.06M Sell
67,500
-45,500
-40% -$613K 0.88% 37
2025
Q3 		$837K Buy
+113,000
New +$598K 0.72% 35

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Rangeley Capital's GLUE Position: Q2 2026 in Review

Rangeley Capital sold out of Monte Rosa Therapeutics (GLUE) in Q2 2026, closing a stake of 27,016 shares — an estimated $444K sold.

Rangeley Capital first reported a position in GLUE in Q3 2025 and held it in 3 quarters. The position peaked at $1.06M in Q4 2025. 192 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Rangeley Capital reported no remaining Monte Rosa Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Rangeley Capital sold 27,016 Monte Rosa Therapeutics shares in Q2 2026, an estimated $444K.
  • Rangeley Capital first reported a position in Monte Rosa Therapeutics in Q3 2025 and held it in 3 quarters.
  • Rangeley Capital's Monte Rosa Therapeutics position peaked at $1.06M in Q4 2025.
  • 192 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Rangeley Capital's 13F filing for Q2 2026, filed 14 Aug 2026.